Views & Analysis | Perspectives on pharma industry issues

R&D

Silhouette of a head with white brain under magnifying glass inside outline, against yellow background

Alzheimer’s: Starting the impossible journey

September was Alzheimer’s Month, and with that in mind pharmaphorum spoke to leaders at two biotechs about latest developments in the field.

Sales & Marketing

Your launch strategy has never met the competition

Will your launch strategy work once it has finally left the meeting room and met the competition?

Oncology

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

Digital

Beyond AI pilots: Pharma needs AI-native operating models, n...

Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.

Views & Analysis

Rare disease insights from the patient community

To help pharma companies understand what life is really like for patients with a rare disease, a new resource has been released to coincide with Rare Disease Day 2021.

Views & Analysis

Building a better future for people with rare diseases in al...

How has rare disease care changed over the last few years? And what might we expect from the next five?

Views & Analysis

2021 market access prospects for Spain

2021 will be the year when big market access changes – including the far wider use of health economic evaluation – are implemented in Spain.

Sales & Marketing

Your launch strategy has never met the competition

Will your launch strategy work once it has finally left the meeting room and met the competition?

Sales & Marketing

Female HCP in her office on phone holding clipboard of patient information

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Digital

Beyond AI pilots: Pharma needs AI-native operating models, n...

Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.

Digital

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Oncology

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

Oncology

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Patients

Maintenance: The underexamined half of the GLP-1 story

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

Patients

Why patient safety doesn't end at approval

Once a treatment becomes available to the public, protecting patient safety remains a priority throughout its time on the market.

Alzheimer’s: Starting the impossible journey

Your launch strategy has never met the competition

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Bioconvergence & future human health, with Shai Melcer

Beyond AI pilots: Pharma needs AI-native operating models, n...

Rare disease insights from the patient community

Building a better future for people with rare diseases in al...

2021 market access prospects for Spain

Your launch strategy has never met the competition

Commercial Evidence: Turning field intelligence into actiona...

Beyond AI pilots: Pharma needs AI-native operating models, n...

Healthcare AI’s off switch needs a budget

Is the next generation of Chinese biotech ready to go global...

What the revised 340B rebate pilot programme means for pharm...

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

In vivo CAR-T can solve the delivery problem – but solid tum...

Unlocking the scalability of allogeneic CAR-T

Rare diseases, real opportunity: Why the UK’s next challenge...

Maintenance: The underexamined half of the GLP-1 story

Why patient safety doesn't end at approval

Alzheimer’s: Starting the impossible journey

Bioconvergence & future human health, with Shai Melcer

Why every healthcare breakthrough creates a new education ch...

Novartis taps China's Abogen for autoimmunity TCE

Discover a new era of healthcare panel engagement: Grounded ...

Sales & Marketing

Digital

Market Access

Editor's Picks

Oncology

Patients

R&D

Editor's Picks